NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/09/2025
Voltar para busca
Dado oficial do USPTO
HAEMATOKINE
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
36
Atualização mais recente
27/09/2025
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
1, 5
Data de depósito
05/02/2021
Data de registro
23/08/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
23/08/2022
Última transação
27/09/2025
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
99
Localização do titular
FI
Examinador
STADELI,MARTA ANN
Unidade examinadora
N50
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Faron Pharmaceuticals Oy
Representantes
Mark E. Olds Muncy, Geissler, Olds & Lowe, P.C.
Classificação técnica
Classes Nice
Classe 1Classe 5
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicals for use in industryscience and photographyas well as in agriculturehorticulture and forestryexcept fungicidesherbicidesinsecticides and parasiticides; Biological preparations for use in industry and science; Media for cell culture for use in the biotechnological industrycell culture media for scientific and research use; Media for cell culture for use in non-medical research laboratoriescell culture media for laboratory use; Biological preparation for use in cell cultures other than for medical or veterinary use; Culture media for microbiologyfor scientific and research use; Cell growth media for growing cells for scientific use; Biological preparation for use in cell culturesother than for medical or veterinary use; Cultures of cell media other than for medical or veterinary usenamely culture media for scientific and research use; Cultures of microorganismsother than for medical and veterinary use; Blood culture media being cell culture media for scientific use; Biological preparations for use in cell culturesother than for medical or veterinary purposes; Stem cellsother than for medical or veterinary purposes; Stem cells for scientific purposes; Stem cells for research purposes
Classe 5
Pharmaceuticalsmedical and veterinary preparations for the treatment of hematological malignanciesbone marrow dysfunction or suppressions; Sanitary preparations for medical purposes; Stem cells for medical or veterinary use; Stem cells for medical purposes; Tumor suppressing agents; Pharmaceutical preparationsantineoplastics; Anti-neoplastic preparations of chemical originpharmaceutical preparations for hematological malignanciesbone marrow dysfunction or suppressions; Anti-neoplastic preparations of microbial originpharmaceutical preparations for hematological malignanciesbone marrow dysfunction or suppressions; Anti-cancer preparations; Compounds for treating canceranti-cancer preparations; Antibodies for medical purposes for the treatment of hematological malignanciesbone marrow dysfunction or suppressions; Antibodies for medical use to treat inflammation and cancer growth and spread; Adjuvants for medical purposes; Vaccine adjuvants; Biological adjuvants for medical purposes; Anti-inflammatories; Antigenstumour antigens for medical diagnostic purposes; Biological preparations for the treatment of cancer; Biopharmaceuticals for the treatment of cancer; Biotechnological preparations for medical usebiological preparations for the treatment of conditions associated with poor production of hematopoietic stem cells; Culture media for medical useculture media for use in augmentation of blood cellsbone marrow and tissues for medical purposes; Media for bacteriological cultures; Cell growth media for growing cells for medical use; Biological preparations for medical purposesbiological preparations for the treatment of hematological malignanciesbone marrow dysfunction or suppressions; Mixed biological preparations for medical purposesmixed biological preparations for the prevention and treatment of infectious diseases; Biological preparations for veterinary purposesbiological preparations for the treatment of hematological malignanciesbone marrow dysfunction or suppressions; Pharmaceutical preparationsimmunomodulators; Immunostimulants; Injectable pharmaceuticals for treatment of hematological malignanciesbone marrow dysfunction or suppressions; Pharmaceutical preparations for the treatment of viral diseases; Pharmaceutical preparations for the treatment of bone diseases; Pharmaceutical preparations for use in chemotherapy; Pharmaceutical preparations for the treatment of infectious diseases; Pharmaceutical preparations for the treatment of immune system related diseases and disorders; Pharmaceutical preparations for use in oncology; Pharmaceutical preparations for activating cellular function; Pharmaceutical preparations for immunity adjustment; Pharmaceutical preparations for regulating the immune system; Pharmaceutical preparations for treating malignant tumors; Pharmaceutical preparations for suppressing tumors; Pharmaceutical preparations for the treatment of autoimmune diseases; Pharmaceutical preparations for the prevention of tumours; Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances with anti-inflammatory properties for treatment of hematological malignanciesbone marrow dysfunction or suppressions; Pharmaceutical preparations and substances for the treatment of cancer; Pharmaceutical preparations for the treatment of autoimmune disorders; Pharmaceutical preparations for use in hematology; Pharmaceutical preparations for the prevention of diseases of the immune system; Pharmaceutical preparations for the prevention of disorders of the immune system; Pharmaceutical preparations for the prevention of autoimmune diseases; Pharmaceutical preparations for the treatment of disorders caused by bacteria; Pharmaceutical preparations for the treatment of diseases caused by bacteria; Pharmaceutical preparations for the prevention of disorders of the respiratory system; Pharmaceutical preparations for the prevention of inflammatory disorders; Pharmaceutical preparations for the prevention of autoimmune disorders; Pharmaceutical preparations for the prevention of inflammatory diseases; Pharmaceutical preparations for the treatment of inflammatory diseases; Pharmaceutical preparations for the treatment of cancer; Pharmaceutical preparations for use in tissue transplantation; Pharmaceutical products for the treatment of bone diseases; Regulatory proteins for medical useprotein arrays for medical diagnosis purposes; Serotherapeutic medicinespharmaceutical preparations for the treatment of hematological malignanciesbone marrow dysfunction or suppressions; Synthetic peptides for pharmaceutical purposes for the treatment of hematological malignanciesbone marrow dysfunction or suppressions; Pharmaceutical products for treating respiratory diseases; Pharmaceutical compounds for treating respiratory diseases; Pharmaceutical preparations for treating respiratory diseases; Pharmaceutical compounds for treating correlated pulmonary syndromes; Pharmaceutical preparations for treatment and prevention of ischemic conditionsinflammation and organ damages resulting from tissue traumasreperfusion injuriescancercancer metastasisinflammatory conditions and allergic conditions; Pharmaceutical preparations for treatment and prevention of multi-organ failureacute lung injury and acute respiratory distress syndrome in adultsadolescentschildreninfants and neonates
Publicações
Histórico de despachos e eventos da marca no USPTO.
36 publicações encontradas
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
28/12/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
01/12/2022
FIMP
FINAL DISPOSITION PROCESSED
01/12/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
23/11/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
23/08/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
23/08/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/06/2022
PUBO
PUBLISHED FOR OPPOSITION
07/06/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
18/05/2022
FIXD
ELECTRONIC RECORD REVIEW COMPLETE
29/04/2022
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
16/04/2022
ERRR
ON HOLD - ELECTRONIC RECORD REVIEW REQUIRED
01/04/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
30/03/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
30/03/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
30/03/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
30/03/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
30/03/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
25/03/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
25/03/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
25/03/2022
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
18/03/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
18/03/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
18/03/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
18/03/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
18/03/2022
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
18/03/2022
RFNT
REFUSAL PROCESSED BY IB
25/10/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
27/09/2021
RFRR
REFUSAL PROCESSED BY MPU
27/09/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
09/09/2021
CNRT
NON-FINAL ACTION WRITTEN
08/09/2021
DOCK
ASSIGNED TO EXAMINER
30/08/2021
MAFR
APPLICATION FILING RECEIPT MAILED
16/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/06/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
10/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace HAEMATOKINE ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.